COVID-19 'seems to love' pharma's biggest production centers

5 March 2020
medicines_supply_europe-_large-1

A worrying aspect of the COVID-19 outbreak, so far as drugmakers and patients are concerned, is that the virus has taken an unerring liking to regions that also happen to be the major production centers for many of the world’s medicines.

The point was made partly in jest by Adrian van den Hoven (pictured above, center), one of the most important figures in ensuring medicine supply to Europe, but he made it to underline the extent of the challenge that the industry could be facing.

Mr van den Hoven is director general of Medicines for Europe, the trade group for generics and biosimilars manufacturers that jointly organized an event in Brussels on Tuesday in the context of new European Commission healthcare priorities. The other organizer was the Hungarian Permanent Representation to the European Union (EU), under the auspice of the Croatian Presidency to the European Council.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics